Skip to main content
. 2020 Sep 22;71(2):331–343. doi: 10.1007/s12020-020-02496-x

Fig. 2.

Fig. 2

Distribution of the reported adverse events (AEs) in the two groups of the treatment: high frequency (HF) and low frequency (LF), and in the Sham group. Data are expressed as percentage (%) of the total AEs in the HF (N. 30, 57.7%), LF (N. 13, 25.0%), and Sham (N. 9, 17.3%) groups